You Position: Home > Paper

Advances in clinical molecular diagnosis and treatment of pulmonary large cell neuroendocrine carcinoma

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Journal of International Oncology
Issue:
7
DOI:
10.3760/cma.j.cn371439-20231130-00077
Key Word:
肺肿瘤;癌,神经内分泌;病理学,分子;肿瘤治疗方案;免疫检查点抑制剂;Lung neoplasms;Carcinoma, neuroendocrine;Pathology, molecular;Antineoplastic protocols;Immune checkpoint inhibitors

Abstract: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare type of malignant neuroendocrine tumor with poor prognosis, with the median overall survival being around one year in advanced diseases. The prognosis of patients with non-small cell lung cancer has been greatly improved with the application of molecular detecting techniques, targeted therapy and immunotherapy. However, little progress has been made in the diagnosis and treatment of LCNEC with no unified standard of diagnosis and treatment protocol. The clinical molecular diagnosis and treatment of LCNEC is of great significance. Exploring the research progress related to the diagnosis and treatment of LCNEC can provide reference for improving the existing clinical diagnosis and treatment difficulties of LCNEC.

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn
Baidu
map